If successful, Sildenafil Cream could become the first FDA-approved treatment for FSAD, addressing a significant unmet need in women's sexual health. The company plans to submit the study protocol ...

We are excited about the potential for Daré’s Sildenafil Cream formulation to address this critical unmet need in women's sexual health, and that there is a clear path forward on how to ...

Some benefits, especially in ability to achieve orgasm, were reported. Men and women who take selective or nonselective serotonin reuptake inhibitors (SRIs) commonly report sexual dysfunction; the ...

Dare Bioscience (DARE) announced plans for a Phase 3 study of Sildenafil Cream, 3.6% ... indication of treatment of FSAD in premenopausal women. As an immediate next step, Dare will submit ...

Use of topical Sildenafil Cream, 3.6% did not produce the common side effects of headache and flushing associated with oral sildenafil use in women. SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE ...

The topical cream, named 0-Cream, contains sildenafil, the same active ingredient ... market comes amid growing interest and investment in women's sexual health. According to McKinsey, the U.S ...

FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sil ...

We are excited about the potential for Daré's Sildenafil Cream formulation to address this critical unmet need in women's sexual health, and that there is a clear path forward on how to evaluate ...

DARE Dare Bioscience Inc Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) ...

To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA approval for FSAD. Market research estimates approximately 10 ...